

Lin Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5310280/publications.pdf>

Version: 2024-02-01

54
papers

1,405
citations

471371

17
h-index

360920

35
g-index

56
all docs

56
docs citations

56
times ranked

2030
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	15.2	322
2	Serum tumor markers for detection of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 1175.	1.4	294
3	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 74-87.	0.4	82
4	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77
5	Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 212-224.	0.4	72
6	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 321-328.	0.7	61
7	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. <i>Nature Cancer</i> , 2022, 3, 753-767.	5.7	41
8	Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis. <i>Oncology Letters</i> , 2016, 12, 1301-1314.	0.8	33
9	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and doseâ€“volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019, 132, 197-203.	0.3	33
10	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016, 96, 93-100.	0.9	32
11	Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis. <i>International Journal of Nanomedicine</i> , 2015, 10, 5205.	3.3	30
12	Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 701951.	2.2	25
13	Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 505-514.	1.0	24
14	Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 1-5.	0.9	23
15	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	0.8	22
16	Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells. <i>Cancer Letters</i> , 2015, 365, 79-88.	3.2	18
17	Epidermal Growth Factor Receptor Mutations in Nonâ€“Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1033-1035.	0.8	18
18	Azithromycin attenuates acute radiationâ€“induced lung injury in mice. <i>Oncology Letters</i> , 2017, 14, 5211-5220.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	0.8	17
20	Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014, 7, 260-266.	0.8	16
21	Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 529-537.	0.4	14
22	Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: An analysis of clinical outcomes. <i>Thoracic Cancer</i> , 2016, 7, 515-521.	0.8	12
23	Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?. <i>Thoracic Cancer</i> , 2020, 11, 631-639.	0.8	11
24	Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with <i>B2M</i> and <i>STK11</i> mutations: a case report. <i>Immunotherapy</i> , 2020, 12, 223-227.	1.0	10
25	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	0.6	9
26	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2589-2598.	1.2	9
27	Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	8
28	Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 647-656.	1.0	7
29	Effective method to reduce the normal brain dose in single-isocenter hypofractionated stereotactic radiotherapy for multiple brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 592-600.	1.0	7
30	Secondary infections after diagnosis of severe radiation pneumonitis (SRP) among non-small cell lung cancer patients: pathogen distributions, choice of empirical antibiotics and the value of empirical antifungal treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	6
31	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 448-466.	0.7	6
32	Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. <i>Thoracic Cancer</i> , 2013, 4, 234-240.	0.8	5
33	The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model. <i>Inflammation</i> , 2017, 40, 1254-1263.	1.7	5
34	Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multicenter prospective study. <i>Thoracic Cancer</i> , 2013, 4, 14-19.	0.8	4
35	Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110119.	0.8	4
36	Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression. <i>Journal of Cancer</i> , 2017, 8, 3682-3688.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	0.8	3
38	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018, 23, 258-265.	1.0	2
39	Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lungâ€molGPA) in a Chinese cohort: A retrospective study of multiple institutions. <i>Cancer Medicine</i> , 2020, 9, 8772-8781.	1.3	2
40	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. <i>Scientific Reports</i> , 2020, 10, 16150.	1.6	2
41	Eye pain and blurred vision as main complaints in a new case with MDPL syndrome. <i>European Journal of Ophthalmology</i> , 2022, 32, NP82-NP86.	0.7	2
42	Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1072-1083.	1.0	2
43	Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21097-e21097.	0.8	2
44	Study of the <i>in vitro</i> â€“ <i>in vivo</i> correlation of Danshensu and protocatechuic aldehyde in a two-step release system. <i>Journal of Asian Natural Products Research</i> , 2015, 17, 391-402.	0.7	1
45	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. <i>Frontiers in Oncology</i> , 2020, 10, 573512.	1.3	1
46	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20543-e20543.	0.8	1
47	A retrospective study of pemetrexed combined with oxaliplatin as secondâ€line treatment for advanced nonâ€smallâ€cell lung cancer: Comparable toxicity, better outcome. <i>Thoracic Cancer</i> , 2011, 2, 201-206.	0.8	0
48	SNAILs promote G1 phase in selected cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 1863-73.	1.4	0
49	Reply to A. Chalmers et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2341-2341.	0.8	0
50	Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21131-e21131.	0.8	0
51	Clinical characteristics of mixed neuroendocrine cancer of lung: Retrospective analysis of 20 cases from 2,501 lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19055-e19055.	0.8	0
52	A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies. <i>Journal of Ophthalmology</i> , 2022, 2022, 1-11.	0.6	0
53	Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21174-e21174.	0.8	0
54	Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20608-e20608.	0.8	0